The increasing incidences of mortality rates on account of liver cancer across the world is boosting the global Hepatocellular carcinoma treatment market, says Fortune Business Insights in their new report. The report is titled, “Hepatocellular Carcinoma (HCC) Treatment Market Size, Share and Global Trend by Treatment (Interventional Radiology, Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, Immunotherapy), By End User (Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgery Centers), and Geography Forecast till 2026.”
Get Sample PDF Brochure at
Some of the major companies that are present in the Global Hepatocellular Carcinoma (Hcc) Treatment Market are
- Novartis Ac
- Bayer AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- CELGENE CORPORATION
- Amgen Inc
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited, and others.
According to this report, the market may be expected to be dominated by the nanoKnife surgery with respect to the treatment segment. It is a minimally invasive option for patients with liver cancer having an inoperable tumor, which is less than three centimeters. This segment is anticipated to gain major revenues in the forecast duration as compared to other treatment methods such as radiofrequency ablation, intra-arterial chemotherapy, chemoembolization, and others.
Segmentation for Hepatocellular Carcinoma (HCC) Treatment Market
- Interventional Radiology
- Radiation Therapy
- Targeted Therapy
By End User
- Cancer Rehabilitation Centers
- Ambulatory Surgery Centers
Rising Incidences of Liver Tumors Creating Lucrative Growth Opportunities for Market
The rising incidences of chronic diseases of the liver are a major factor propelling growth of the global Hepatocellular carcinoma treatment market. Also known by the name, malignant hepatoma, it is the major cause of liver malfunction leading to cirrhosis. These tumors multiply with local expansion, that spreads into the intrahepatic region and then distant metastases. The rising number of cases of these tumors occurring in a majority of people is adding boost to the global Hepatocellular carcinoma market during the forecast period.
On the flipside, the market may face challenges in terms of risks associated with post surgical treatments. These include Hepatitis B virus (HBV) infection, metabolic syndrome, alcoholic cirrhosis, Hepatitis C virus (HCV) infection, chronic liver injury, and biliary cirrhosis. Again, the side effects of chemotherapy such as hair fall may also restrict the growth of the Hepatocellular carcinoma market in the long run. Another major challenge for the growth of the market is the high cost of treatment and unavailability of reimbursement policies in developing nations.
Nevertheless, the increasing incidences of hepatic cancer namely intrahepatic bile duct cancer especially in developed nations of the U.S. are a major driver for the market to grow remarkably in future.
Browse Complete Report Details at
Europe and Asia Pacific to Show Promising Growth Owing to Rising Number of Liver Cancer Cases
Fortune Business Insights foresees the global Hepatocellular carcinoma treatment market to be dominated by North America. This is because of the rising prevalence of the chronic liver diseases, coupled with the increasing number of liver diseases in the region. A survey conducted in 2017 by the Health Science Department, University of California, Los Angeles stated that 70% of all liver cancer cases is registered in the U.S. with an estimated 40,000 people diagnosed and 28,000 deaths reported due to Hepatocellular carcinoma.
Additionally, the market in Asia Pacific and Europe is also expected to show remarkable growth during the forecast duration. This is attributable to the rising number of research and development projects conducted in the regions for discovering better therapeutics. The World Health Organization conducted a survey in 2017 in the regions and states that an estimated 63,000 people were diagnosed with liver cancer in Europe and about 36,000 people were diagnosed with liver cancer in Japan. Such high occurrence of liver cancer in the regions is expected to open great opportunities of growth for the Hepatocellular carcinoma treatment market in the respective regions.
KEY QUESTIONS ANSWERED:
- What is the market size and growth rate of the global and regional market by various segments?
- What is the market size and growth rate of the market for selective countries?
- Which region or sub-segment is expected to drive the market in the forecast period?
- What Factors are estimated to drive and restrain the market growth?
- What are the key technological and market trends shaping the market?
- What are the key opportunities in the market?
- What are the key companies operating in the market?
- Which company accounted for the highest market share?
- Why Choose Fortune Business Insights?
View Related Report at
Global Population Health Management Market to Get a Boost as Governments Look to Digitize Healthcare Infrastructure